DK1009399T3 - GABA-analoger til forebyggelse og behandling af gastrointestinal skade - Google Patents

GABA-analoger til forebyggelse og behandling af gastrointestinal skade

Info

Publication number: DK1009399T3
Authority: DK; Denmark
Prior art keywords: prevention; treatment; gastrointestinal injury; gaba analogues; gaba
Prior art date: 1997-08-20

Application number

DK98945758.5T

Other languages

English (en)

Inventor

Antonio Guglietta

Charles Price Taylor Jr

Jiayuan Ren

W P Watson

Michael Francis Rafferty

Laurent Diop

Maria Chovet

Lionel Bueno

Hilary J Little

Original Assignee

Warner Lambert Co

Regents For The University Of

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-20

Filing date

1998-08-18

Publication date

2010-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1009399(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-08-18 Application filed by Warner Lambert Co, Regents For The University Of filed Critical Warner Lambert Co

2010-05-31 Application granted granted Critical

2010-05-31 Publication of DK1009399T3 publication Critical patent/DK1009399T3/da

Links

BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
206010061172 Gastrointestinal injury Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
229960002870 gabapentin Drugs 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
229960001233 pregabalin Drugs 0.000 abstract 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Addiction (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

DK98945758.5T 1997-08-20 1998-08-18 GABA-analoger til forebyggelse og behandling af gastrointestinal skade DK1009399T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US5675397P	1997-08-20	1997-08-20
US7479498P	1998-02-16	1998-02-16
US8293698P	1998-04-24	1998-04-24
PCT/US1998/017082 WO1999008671A1 (en)	1997-08-20	1998-08-18	Gaba analogs to prevent and treat gastrointestinal damage

Publications (1)

Publication Number	Publication Date
DK1009399T3 true DK1009399T3 (da)	2010-05-31

Family

ID=27369092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98945758.5T DK1009399T3 (da)	1997-08-20	1998-08-18	GABA-analoger til forebyggelse og behandling af gastrointestinal skade

Country Status (25)

Country	Link
US (2)	US6242488B1 (da)
EP (1)	EP1009399B1 (da)
JP (1)	JP4681116B2 (da)
KR (2)	KR20050116168A (da)
AT (1)	ATE461698T1 (da)
AU (2)	AU8668598A (da)
BR (1)	BR9812133A (da)
CA (1)	CA2297163C (da)
CO (1)	CO4960645A1 (da)
CY (1)	CY1109981T1 (da)
DE (1)	DE69841574D1 (da)
DK (1)	DK1009399T3 (da)
ES (1)	ES2341154T3 (da)
HU (1)	HUP0004551A3 (da)
IL (1)	IL134164A (da)
IS (1)	IS2749B (da)
MY (1)	MY155223A (da)
NO (1)	NO327983B1 (da)
NZ (1)	NZ502729A (da)
PE (1)	PE107299A1 (da)
PL (1)	PL194125B1 (da)
PT (1)	PT1009399E (da)
TW (2)	TW570794B (da)
UY (1)	UY25148A1 (da)
WO (2)	WO1999008670A1 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001876A (en)	1996-07-24	1999-12-14	Warner-Lambert Company	Isobutylgaba and its derivatives for the treatment of pain
EP1011658B1 (en)	1997-09-08	2005-12-07	Warner-Lambert Company Llc	Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1031350A1 (en) *	1999-02-23	2000-08-30	Warner-Lambert Company	Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
JP2002538221A (ja) *	1999-03-10	2002-11-12	ワーナー−ランバート・カンパニー	抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
WO2000061188A1 (en) *	1999-04-09	2000-10-19	Euro-Celtique S.A.	Sodium channel blocker compositions and the use thereof
EP1840117A1 (en) *	1999-06-10	2007-10-03	Warner-Lambert Company LLC	Mono- and disubstituted 3-propyl gamma-aminobutyric acids
NZ517044A (en)	1999-07-22	2004-02-27	Univ Rochester	Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
FR2801217B1 (fr) *	1999-11-24	2002-12-06	Aventis Pharma Sa	Association de riluzole et de gabapentine et son utilisation comme medicament
AU2001259627A1 (en)	2000-05-16	2001-11-26	Warner Lambert Company	Cell line for the expression of an alpha2delta2 calcium channel subunit
EP1361847A2 (en)	2000-10-06	2003-11-19	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en)	2000-10-06	2002-04-15	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1226820A1 (en) *	2001-01-26	2002-07-31	Warner-Lambert Company	Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
MXPA03011566A (es)	2001-06-11	2004-10-28	Xenoport Inc	Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7420002B2 (en)	2001-06-11	2008-09-02	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
SI1423168T1 (sl)	2001-09-03	2006-06-30	Newron Pharm Spa	Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
US20060159743A1 (en) *	2001-10-25	2006-07-20	Depomed, Inc.	Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) *	2001-10-25	2007-08-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
US6927036B2 (en)	2002-02-19	2005-08-09	Xero Port, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
PL372210A1 (en) *	2002-02-22	2005-07-11	Warner-Lambert Company Llc	Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
US7026351B2 (en)	2002-03-20	2006-04-11	Xenoport, Inc.	Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
AU2003243180A1 (en)	2002-05-17	2003-12-12	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004006901A1 (en) *	2002-07-10	2004-01-22	Warner-Lambert Company Llc	Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) *	2002-10-07	2006-04-11	Advanced Cardiovascular Systems, Inc.	Method of making a catheter balloon using a tapered mandrel
US20040105881A1 (en) *	2002-10-11	2004-06-03	Gregor Cevc	Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7060727B2 (en)	2002-12-11	2006-06-13	Xenoport, Inc.	Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
DE60332387D1 (de) *	2002-12-13	2010-06-10	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
MXPA05006209A (es) *	2002-12-13	2005-08-19	Warner Lambert Co	Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
JP2006519831A (ja)	2003-03-07	2006-08-31	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	テトラゾール及びオキサジアゾロン置換β−アミノ酸誘導体
WO2004084881A1 (en) *	2003-03-21	2004-10-07	Dynogen Pharmaceuticals, Inc.	METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
KR20060119971A (ko)	2003-09-11	2006-11-24	제노포트 인코포레이티드	Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
WO2005027850A2 (en)	2003-09-17	2005-03-31	Xenoport, Inc.	Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es)	2003-10-14	2006-06-27	Xenoport Inc	Forma cristalina de un analogo del acido gamma-aminobutirico.
WO2005060968A1 (en)	2003-12-11	2005-07-07	Sepracor Inc.	Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
DE602005002253T2 (de) *	2004-03-12	2008-05-29	Warner-Lambert Company Llc	C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
ES2309731T3 (es) *	2004-04-01	2008-12-16	Warner-Lambert Company Llc	Preparacion de fosfolanos p-quirogenicos y su uso en sintesis asimetrica.
AP2466A (en) *	2004-06-21	2012-09-17	Warner Lambert Co	Preparation of pregabalin and related compounds
US20080096965A1 (en) *	2004-09-10	2008-04-24	Newron Pharmaceuticals S.P.A.	(Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
EP1811986B1 (en)	2004-11-04	2014-03-26	XenoPort, Inc.	Gabapentin prodrug sustained release oral dosage forms
EP1963280B1 (en) *	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylamino derivatives as calcium and/or sodium channel modulators
US20090176882A1 (en) *	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
BRPI0720252A2 (pt) *	2006-12-08	2014-01-07	Xenoport Inc	Uso de pró-fármacos de análogos de gaba para tratar doenças
WO2009055059A1 (en) *	2007-10-26	2009-04-30	The Scripps Research Institute	Methods for treating substance dependence
US7872046B2 (en)	2008-01-25	2011-01-18	Xenoport, Inc.	Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250143B1 (en)	2008-01-25	2016-04-20	XenoPort, Inc.	Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
ES2589915T3 (es)	2008-10-08	2016-11-17	Xgene Pharmaceutical Inc	Conjugados de GABA y métodos de utilización de los mismos
KR101429331B1 (ko) *	2009-06-22	2014-08-11	와이어쓰 엘엘씨	이부프로펜 나트륨 정제 및 이부프로펜 나트륨을 포함하는 제약 조성물의 제조 방법
WO2011141923A2 (en)	2010-05-14	2011-11-17	Lupin Limited	Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en)	2010-11-04	2012-05-10	Lupin Limited	Process for synthesis of (s) - pregabalin
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
WO2014117176A1 (en)	2013-01-28	2014-07-31	Lopez Hector L	Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105997970A (zh) *	2015-12-16	2016-10-12	南昌大学	γ-氨基丁酸在制备胃粘膜保护剂中的应用
US10052296B2 (en)	2016-04-07	2018-08-21	Nevakar Inc.	Formulations for treating pain
JP7249670B2 (ja)	2017-10-03	2023-03-31	ネヴァカーインジェクテーブルズインコーポレイテッド	アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法
CA3099775A1 (en)	2018-05-14	2019-11-21	Xgene Pharmaceutical Inc.	Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
CN116999560A (zh) *	2022-04-30	2023-11-07	武汉思瓴生物科技有限公司	可治疗疼痛的药物组合及其应用
EP4648757A4 (en) *	2023-02-17	2026-01-07	Ovid Therapeutics Inc	USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATING AGENT

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE634102A (da)
DE1966802C3 (de)	1969-12-20	1975-11-06	Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg	5,5-Diphenylhydantoin-N hoch 3 -carbonsäureester
JPS54110334A (en)	1978-02-16	1979-08-29	Fuji Chem Ind Co Ltd	Novel compounded anodyne and antiiinflammatory agent
US4158581A (en)	1978-04-14	1979-06-19	Westinghouse Electric Corp.	Method of making magnetic component for direct current apparatus
JPS61221121A (ja)	1985-03-27	1986-10-01	Nitto Electric Ind Co Ltd	テ−プ製剤
US4694010A (en)	1985-08-16	1987-09-15	New York University	Anticonvulsant compositions and method
AU2929489A (en)	1987-12-22	1989-07-19	John W. FERKANY	Dextrorphan potentiator for anticonvulsant composition and method
AU9137091A (en)	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en)	1991-04-18	1991-06-05	Radoslavov Alexander	A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
RU94046105A (ru) *	1992-05-20	1997-06-20	Нортвестерн Юниверсити (Us)	АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US5234929A (en)	1992-07-20	1993-08-10	William Chelen	Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja)	1992-09-25	1994-04-12	Kibun Food Chemifa Co Ltd	徐放性組成物
US5321012A (en)	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja)	1993-02-02	1994-08-16	Masayasu Sugihara	薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en)	1993-10-07	1995-05-30	G. D. Searle & Co.	Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en)	1994-02-22	1994-10-04	Corning Incorporated	Nickel aluminosilicate glass-ceramics
DE69532285T2 (de)	1994-09-02	2004-09-23	Virginia Commonwealth University	Zusammensetzung zur verminderung von schmerzen, die ein nicht narkotisches analgetika und ein analgetikabekräftiger enthält
GB9420784D0 (en) *	1994-10-14	1994-11-30	Glaxo Group Ltd	Medicaments
CN1046199C (zh)	1994-12-13	1999-11-10	凌吉安	复方消炎止痛霜剂
CA2264182A1 (en) *	1996-08-23	1998-02-26	Algos Pharmaceutical Corporation	Anticonvulsant containing composition for treating neuropathic pain
SE9603408D0 (sv) *	1996-09-18	1996-09-18	Astra Ab	Medical use
NZ334898A (en) *	1996-10-23	2000-09-29	Warner Lambert Co	Substituted gamma aminobutyric acids as pharamceutical agents
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage

1998
- 1998-07-29 AU AU86685/98A patent/AU8668598A/en not_active Withdrawn
- 1998-07-29 WO PCT/US1998/015694 patent/WO1999008670A1/en not_active Ceased
- 1998-08-18 TW TW087113592A patent/TW570794B/zh not_active IP Right Cessation
- 1998-08-18 DK DK98945758.5T patent/DK1009399T3/da active
- 1998-08-18 JP JP2000509411A patent/JP4681116B2/ja not_active Expired - Fee Related
- 1998-08-18 TW TW092130045A patent/TWI251485B/zh not_active IP Right Cessation
- 1998-08-18 AU AU92930/98A patent/AU9293098A/en not_active Abandoned
- 1998-08-18 NZ NZ502729A patent/NZ502729A/xx not_active IP Right Cessation
- 1998-08-18 DE DE69841574T patent/DE69841574D1/de not_active Expired - Lifetime
- 1998-08-18 AT AT98945758T patent/ATE461698T1/de active
- 1998-08-18 WO PCT/US1998/017082 patent/WO1999008671A1/en not_active Ceased
- 1998-08-18 MY MYPI98003770A patent/MY155223A/en unknown
- 1998-08-18 KR KR1020057022543A patent/KR20050116168A/ko not_active Ceased
- 1998-08-18 EP EP98945758A patent/EP1009399B1/en not_active Expired - Lifetime
- 1998-08-18 CA CA002297163A patent/CA2297163C/en not_active Expired - Lifetime
- 1998-08-18 IL IL13416498A patent/IL134164A/xx not_active IP Right Cessation
- 1998-08-18 ES ES98945758T patent/ES2341154T3/es not_active Expired - Lifetime
- 1998-08-18 HU HU0004551A patent/HUP0004551A3/hu unknown
- 1998-08-18 BR BR9812133-2A patent/BR9812133A/pt not_active Application Discontinuation
- 1998-08-18 KR KR1020007001703A patent/KR100609359B1/ko not_active Expired - Fee Related
- 1998-08-18 PL PL98338705A patent/PL194125B1/pl not_active IP Right Cessation
- 1998-08-18 PT PT98945758T patent/PT1009399E/pt unknown
- 1998-08-19 CO CO98047372A patent/CO4960645A1/es unknown
- 1998-08-19 PE PE1998000745A patent/PE107299A1/es not_active Application Discontinuation
- 1998-08-20 UY UY25148A patent/UY25148A1/es unknown
2000
- 2000-01-25 IS IS5361A patent/IS2749B/is unknown
- 2000-02-17 NO NO20000786A patent/NO327983B1/no not_active IP Right Cessation
- 2000-05-09 US US09/567,191 patent/US6242488B1/en not_active Expired - Fee Related
2001
- 2001-03-13 US US09/804,742 patent/US6426368B2/en not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100368T patent/CY1109981T1/el unknown

Also Published As

Publication number	Publication date
IS2749B (is)	2011-08-15
PE107299A1 (es)	1999-12-19
ES2341154T3 (es)	2010-06-15
NO20000786L (no)	2000-02-17
EP1009399A1 (en)	2000-06-21
WO1999008670A1 (en)	1999-02-25
JP4681116B2 (ja)	2011-05-11
JP2001515033A (ja)	2001-09-18
KR20050116168A (ko)	2005-12-09
NZ502729A (en)	2002-10-25
CY1109981T1 (el)	2014-09-10
WO1999008671A1 (en)	1999-02-25
TWI251485B (en)	2006-03-21
ATE461698T1 (de)	2010-04-15
UY25148A1 (es)	1999-01-26
US20010014698A1 (en)	2001-08-16
BR9812133A (pt)	2000-07-18
HUP0004551A2 (hu)	2001-05-28
MY155223A (en)	2015-09-30
US6242488B1 (en)	2001-06-05
PL194125B1 (pl)	2007-04-30
PT1009399E (pt)	2010-05-21
EP1009399B1 (en)	2010-03-24
TW570794B (en)	2004-01-11
DE69841574D1 (de)	2010-05-06
IS5361A (is)	2000-01-25
AU9293098A (en)	1999-03-08
CA2297163A1 (en)	1999-02-25
AU8668598A (en)	1999-03-08
TW200412938A (en)	2004-08-01
US6426368B2 (en)	2002-07-30
NO327983B1 (no)	2009-11-02
HUP0004551A3 (en)	2002-11-28
KR100609359B1 (ko)	2006-08-04
NO20000786D0 (no)	2000-02-17
IL134164A (en)	2005-05-17
CO4960645A1 (es)	2000-09-25
IL134164A0 (en)	2001-04-30
KR20010023084A (ko)	2001-03-26
PL338705A1 (en)	2000-11-20
CA2297163C (en)	2001-11-20

Publication	Publication Date	Title
NO20000786D0 (no)	2000-02-17	GABA analoger for forebyggelse og behandling av gastrointestinal skade
DK0971713T3 (da)	2003-09-22	Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0934061T3 (da)	2003-09-22	Isobutylgaba og dets derivater til behandling af smerte
FI945426A7 (fi)	1994-11-18	GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn
DK0840606T3 (da)	2000-08-07	Små di- og trivalente molekyler som selectininhibitorer
GB2396108B (en)	2005-08-03	Treatment of pain
ES2164447T3 (es)	2002-02-16	Procedimiento de inhibicion de resorcion del hueso.
DK0994704T3 (da)	2005-10-03	Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
NO984760L (no)	1998-10-12	Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
DK0888330T3 (da)	2003-09-01	Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis
ATE290384T1 (de)	2005-03-15	Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
EP0974351A3 (en)	2000-12-13	Medicament for preventing and treating gastrointestinal damage
BR0114604A (pt)	2003-10-14	Tratamento de cnceres
MX9204528A (es)	1993-02-01	0etodo para tratar el sindrome premenstrual mediante administracion de un inhibidor de la enzima de conversion de angiotensina.
ECSP982631A (es)	1999-04-16	Metodo para prevenir y tratar lesiones gastrointestinales
DE69626307D1 (de)	2003-03-27	Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
ATE369847T1 (de)	2007-09-15	Aminoguanidine zur behandlung von diabetes typ ii
ATE305778T1 (de)	2005-10-15	Behandlung von nierenkolik mit gaba-analogen
BR9812265A (pt)	2000-07-18	Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias.